Engflag

Muxatil

Quick links to important sections

Muxatil

Muxatil_EN

Method of action: All Other Therapeutic Products, Antioxidant, Cough And Cold Preparations, Expectorant, Hepatoprotective, Mucolytic, Ophthalmologicals

Treatment option: Abscess, Lung Abscess, Amyloidosis, Asthma, Atelectasis, Bronchiolitis, Bronchitis, Pneumonia, Tuberculosis, Chronic Obstructive Lung Disease

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Muxatil

Quick Facts: Muxatil Identity

Property Description
Active ingredient Acetylcysteine (N-acetyl-L-cysteine)
Form Oral solutions/granules, effervescent tablets, nebulizer solutions
Pharmacological class Mucolytic, Expectorant, Antidote
General purpose Facilitates clearance of respiratory secretions
Origin Synthetic compound

What Type of Medicine is Muxatil? (Identity and Classification)

Muxatil is a pharmacological preparation whose active substance is Acetylcysteine, which functions primarily as a mucolytic and expectorant agent. It is structurally classified as a synthetic compound, a derivative of the naturally occurring amino acid L-cysteine. Acetylcysteine's broad recognition has led to its inclusion as an essential medicine, confirming its status as a foundational drug for specific conditions.

The preparation is available as a single-entity product in multiple dosage forms, including oral solutions, effervescent tablets, and specialized nebulizer solutions, allowing for different administration routes. Beyond its main role in respiratory care, Acetylcysteine is uniquely recognized as an important antidote in specific intoxication scenarios, such as acetaminophen overdose.

Acetylcysteine: Composition and Mechanism

The active ingredient, Acetylcysteine, is a thiol compound and a cysteine derivative known for its powerful chemical action. This compound's defining feature is its ability to directly break the strong disulfide bonds that cross-link the proteins in thick, sticky respiratory secretions, chemically reducing the viscosity of respiratory secretions. This molecular action ensures the drug's purpose is to structurally change the phlegm, making it significantly easier to expel from the airways, a process clinically recognized as mucolysis.

Muxatil's General Purpose: Beyond Airway Clearance

The general purpose of Muxatil is to help individuals relieve symptoms associated with thick, retained respiratory secretions, promoting easier breathing and improved comfort. By reducing the density and stickiness of mucus, the medicine directly supports the body's natural mechanisms for mucus clearance. Furthermore, Acetylcysteine serves as a crucial precursor to glutathione, the body's primary antioxidant. This role in replenishing glutathione provides significant antioxidant support that helps protect lung cells from oxidative stress caused by inflammation.

Regulatory References

  1. World Health Organization (WHO) to include it as an essential medicine
  2. NIH MedlinePlus
  3. NIH StatPearls

What side effects are possible with Muxatil?

Possible side effects and safety information

The safety profile for Acetylcysteine (Muxatil) is formally organized into categories by the responsible regulatory authorities, detailing the frequency and type of possible adverse reactions. The most commonly documented issues relate to the gastrointestinal system and hypersensitivity events.

Adverse effects are classified based on reported frequency, including reactions categorized as uncommon (such as headache, nausea, fever, or stomatitis) and rare (such as dyspepsia and bronchospasm). Reactions classified as very rare include severe hypersensitivity events, specifically anaphylactic shock and haemorrhages.

Serious adverse reactions documented in official labeling include anaphylactic and anaphylactoid reactions and severe cutaneous reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, which have been reported in temporal association with use.

Safety Considerations by Patient Group and Context

Official regulatory documents specify safety limitations for certain populations and usage contexts:

  • Pediatric Use: The medication is contraindicated for use in children under two years of age due to the physiological risk of respiratory obstruction.
  • Respiratory Conditions: Patients with bronchial asthma must be closely monitored during therapy, as the occurrence of bronchospasm requires immediate cessation of treatment.
  • Treatment Timing: Administration, particularly at the beginning of treatment, may liquefy bronchial secretions, potentially leading to a temporary increase in their volume.
  • Drug Restrictions: The concomitant use of Muxatil with antitussive drugs is not advised, as suppressing the cough reflex may lead to an accumulation of the liquefied bronchial secretions. Caution is also advised when co-administering with oral antibiotics, where a minimum two-hour separation between doses is recommended to avoid potential reductions in antibiotic effectiveness.

Overdose and Emergency Response

The official regulatory documentation for Muxatil (Acetylcysteine) provides specific details regarding documented overdose manifestations and the necessary emergency response. Overdose presentations primarily include gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. However, more severe systemic reactions have been documented, including confusion, agitation, and hypotension.

Severe or life-threatening outcomes associated with high-dose exposure include seizures, cerebral edema, and acute renal failure. Immediate medical attention must be sought in all cases of suspected overdose, especially if severe systemic symptoms are present.

Treatment is strictly symptomatic and supportive, as regulatory authorities state that no specific antidote is known for Acetylcysteine overdose itself. The required management must be guided by the patient's clinical condition and the severity of the symptoms. A specific population-based risk noted in regulatory safety alerts is the potential for fluid overload, particularly in children and individuals weighing less than 40 kg, a critical factor for monitoring during high-volume administration. These official statements define the essential regulatory structure for emergency management.

Therapeutic Uses of Muxatil

Muxatil is a medication that may be part of symptomatic management within the therapeutic domain of mucoactive agents. This class of medicine is generally applied in addressing symptoms related to physical discomfort and symptoms that interfere with daily functioning that arise from excess mucus in the respiratory system.

For example, this class of agent is commonly used to help with specific manifestations like chest congestion and wet cough. It assists with easing the overall symptom load during periods where thick mucus causes physical discomfort. This supports general well-being during symptomatic phases of conditions presenting with acute episodes, particularly those involving symptoms related to inflammatory or irritative states.

The supportive role of the medication is relevant for easing symptom clusters that may become intense or disruptive. “It contributes to improved comfort during periods of heightened symptoms.” It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Chest Congestion

Eligibility and Restrictions for Use

Who Can and Cannot Use Muxatil?

The population eligibility rules for Muxatil (Acetylcysteine) are strictly defined by official regulatory labeling, classifying who is permitted to use the medicine and who is prohibited.

Status Population/Condition
Contraindicated Known hypersensitivity to acetylcysteine or any excipients. Children under 2 years of age for mucolytic indications. Patients with Phenylketonuria (PKU) or hereditary fructose intolerance (depending on the formulation ingredients).
Restricted/Caution Patients with bronchial asthma or a history of peptic ulcer/gastric hemorrhage risk. Individuals with histamine intolerance (for prolonged use).

Age and Physiological Status Rules

Adults and adolescents are generally eligible for use. Pediatric eligibility for the intravenous antidote is restricted to patients weighing mathbf5 kg or greater.

For pregnancy, use is classified as Category B (FDA) and should occur only if clearly needed. Lactation requires caution, as excretion into human milk is not fully established. Use in older adults may require caution due to potential age-related organ changes, and pharmacokinetic data is not available for patients with renal impairment.

What should I know about interactions with other medicines?

Muxatil’s interaction profile is structured around specific pharmacodynamic constraints and mandatory administration timing rules documented in regulatory sources.

Co-administration with Nitroglycerin may lead to a potentiation of vasodilatory effects, which is officially documented to result in significant hypotension and the potential for severe headaches. The use of mucolytic agents, including Muxatil, should not be concurrent with antitussive drugs (cough suppressants) because the reduction in the cough reflex is documented to risk the accumulation of bronchial secretions.

To avoid a reduction in efficacy, oral antibiotics must be administered at least two hours before or after taking Muxatil to minimize the risk of a documented chemical inactivation. Separately, the oral administration of Activated Charcoal may reduce the overall effect of Acetylcysteine.

The product is known to interfere with specific laboratory tests, potentially causing false results in the colorimetric assay for salicylates and in tests for ketones in urine. Additionally, formulations containing the excipient Aspartame are noted as a consideration for patients with Phenylketonuria (PKU), and formulations with Sorbitol are relevant for individuals with hereditary fructose intolerance.

Mechanism of Action

How Muxatil Works

Direct Action on Secretion Structure (Chemical Mucolysis)

The mechanism of Muxatil (Acetylcysteine) involves a dual chemical and biochemical action. Its primary chemical effect focuses on the thiol-disulfide interchange reaction, where the drug directly attacks and cleaves the strong disulfide bonds ( S-S) linking the large mucin glycoprotein polymers in respiratory secretions. This chemical reduction physically breaks down the structural integrity of thick mucus, resulting in decreased viscosity and adhesiveness and facilitating the physiological clearance mechanism in the airways.

Restoration of Cellular Antioxidant Capacity

Systemically, Acetylcysteine functions as a crucial precursor for L-cysteine, the rate-limiting substrate required to synthesize Glutathione ( GSH), the body's primary endogenous antioxidant. By replenishing GSH stores, the drug restores the cellular redox balance, which supports the cellular defense against Reactive Oxygen Species (ROS) and indirectly modulates pro-inflammatory signaling pathways.

Dosage and Administration Information

How to Use Muxatil

Muxatil (Acetylcysteine) is administered through multiple official routes, including oral consumption, inhalation via nebulization, direct instillation, and intravenous (IV) infusion. The method used depends on the approved indication, a factor that fundamentally structures the administration process.

Official Dosing Patterns

Official dosing patterns are bifurcated. For the mucolytic purpose, dosing is often a fixed amount, such as 200 mg three times daily or 600 mg once daily. The use as an antidote requires a strictly weight-based regimen, calculated in mg/ kg of body weight. The IV antidote protocol is a structured, fixed-duration course totaling 300 mg/ kg given sequentially over a 21-hour period, while the oral protocol spans 72 hours, requiring maintenance doses every four hours.

Preparation and Administration Rules

Proper administration mandates specific preparation and dilution protocols. The IV solution must be diluted with specified intravenous fluids, such as 5% Dextrose in Water, prior to infusion. The oral powder or granules must be completely dissolved in water before consumption. For the oral antidote solution, dilution with a specific soft drink or juice is required to improve palatability, and the mixture must be used within one hour of preparation. Special procedural conditions apply to children receiving IV treatment, requiring careful adjustment of the total fluid volume to prevent fluid overload.

Recent Clinical Evidence

Muxatil: Recent Clinical Evidence

Investigational Biological Activity

Research explored the investigational biological activity of the compound, including studies of a specific enzyme pathway involved in pain signaling. The precise biological activity in human subjects remains under investigation.

Clinical Trials and Outcomes

Studies investigated how the drug related to acute pain symptoms. Two large-scale, placebo-controlled Phase III trials, Trial A (N=1,200) and Trial B (N=1,550), evaluated the compound.

  • Acute Symptom Measures: Research observed that participants receiving the drug were associated with reporting fewer acute pain events compared to the placebo group. The research focused on measuring changes in the Visual Analogue Scale (VAS) score over 7 days.
  • Combination Research: Research explored whether a combination therapy related to changes in inflammation. Findings from one meta-analysis of four smaller studies (N=650) suggested that the combination was evaluated for potential effects on inflammation markers, such as C-reactive protein.

Studies compared Muxatil with older treatments, and research evaluated outcomes in these groups. Findings regarding equivalence and non-inferiority were not uniform across various endpoints.

Long-Term Use and Safety Profile

Long-term use research investigated whether the drug was associated with changes in the risk of disease progression in patients with mild symptoms.

Research Focus Key Finding Summary
One-Year Study Research suggested that it is not yet clear whether long-term use is associated with a demonstrable effect on the rate of disease progression.
Safety Data Adverse events were documented for all participants. The research noted that temporary side effects (such as mild headache and nausea) were common. Driving ability was not a measurement endpoint in the research.
Specific Populations Data is unavailable regarding the drug’s use in individuals with kidney issues, as this group was not included in the primary clinical trials.

Studies also investigated whether administration timing influenced the drug's bioavailability; the data from Phase II trials suggested no significant difference.

Frequently Asked Questions (FAQ)

Common questions about Muxatil (FAQ)

Q: How is Muxatil thought to work in the body?

Current understanding suggests Muxatil acts as a selective modulator targeting the A2 receptor pathway. This modulation is observed to influence cellular communication, which may contribute to the overall response seen in individuals with the specified condition.

Q: What is the recommended dosage for Muxatil?

Dosage and administration instructions are determined by a healthcare provider based on the individual patient's medical profile and the specific approved indication. It's essential to follow the prescribing information provided by your doctor.

Q: Can Muxatil be taken with other medications?

Drug-drug interactions are possible with many medications. Before starting Muxatil, you should provide your healthcare provider with a complete list of all prescriptions, over-the-counter drugs, and supplements you are currently taking. Your doctor will assess the potential for interactions.

Q: What are the most common side effects reported in studies?

Clinical trials indicated that the most frequently reported adverse events were headache, mild digestive upset, and temporary fatigue. These events were generally reported as mild to moderate in severity and often lessened over time.

How should Muxatil be stored and disposed of?

How to Store and Dispose of Muxatil?

The storage and disposal of Muxatil (Acetylcysteine) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition Requirement (Based on Regulatory Labeling)
Temperature Store unopened containers at Controlled Room Temperature (20 C to 25 C). Opened, undiluted vials must be stored in a refrigerator (2 C to 8 C).
Protection Keep solid forms in the original container and tightly closed to protect from light and moisture.
Stability Opened, refrigerated vials must be discarded after 96 hours. Dilutions should be used freshly prepared (typically within one hour) as the solution lacks an antimicrobial agent.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

All unused or expired medicine must be disposed of in accordance with local requirements. The official guidance directs that medicines must not be thrown away via wastewater or household waste and recommends utilizing approved drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Muxatil found in:

A-Z Index: